Common and divergent pathways in early stages of glutamate and tau-mediated toxicities in neurodegeneration.

Exp Neurol

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States of America; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States of America; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States of America. Electronic address:

Published: December 2024

AI Article Synopsis

  • Excitotoxicity and tau-mediated toxicities are key factors in neuronal death related to Alzheimer's disease (AD), with issues like glutamate levels being critical.
  • *The main glutamate transporter, EAAT2 (GLT-1), is deficient in AD brains, leading to cell death from excitotoxicity, while tau protein buildup correlates with cognitive decline.
  • *Research using mouse models revealed that GLT-1 deficiency affects pathways linked to neuronal survival, while tau mutations disrupt endocytic pathways and mitochondria, highlighting potential therapeutic targets.*

Article Abstract

It has been shown that excitotoxicity and tau-mediated toxicities are major contributing factors to neuronal death in Alzheimer's disease (AD). The excitatory amino acid transporter 2 (EAAT2 or GLT-1), the major glutamate transporter in the brain that regulates glutamate levels synaptically and extrasynaptically, has been shown to be deficient in AD brains, leading to excitotoxicity and subsequent cell death. Similarly, buildup of neurofibrillary tangles, which consist of hyperphosphorylated tau protein, correlates with cognitive decline and neuronal atrophy in AD. However, common genes and pathways that are critical in the aforementioned toxicities have not been well elucidated. To investigate the impact of glutamate dyshomeostasis and tau accumulation on translational profiles of affected hippocampal neurons, we used mouse models of excitotoxicity and tau-mediated toxicities (GLT-1 and P301S, respectively) in conjunction with BAC-TRAP technology. Our data show that GLT-1 deficiency in CA3 pyramidal neurons leads to translational signatures characterized by dysregulation of pathways associated with synaptic plasticity and neuronal survival, while the P301S mutation induces changes in endocytic pathways and mitochondrial dysfunction. Finally, the commonly dysregulated pathways include impaired ion homeostasis and metabolic pathways. These common pathways may shed light on potential therapeutic targets for ameliorating glutamate and tau-mediated toxicities in AD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2024.114967DOI Listing

Publication Analysis

Top Keywords

tau-mediated toxicities
16
glutamate tau-mediated
8
excitotoxicity tau-mediated
8
pathways
7
glutamate
5
toxicities
5
common divergent
4
divergent pathways
4
pathways early
4
early stages
4

Similar Publications

Polyserine domains mediate the association of nuclear RNA binding proteins with cytoplasmic tau aggregates that occurs across tauopathy models and patient samples. In cell lines, polyserine peptides co-localize with and promote formation of tau aggregates suggesting the cytoplasmic mislocalization of polyserine-containing proteins might contribute to human disease. Moreover, polyserine can be produced by repeat associated non-AUG translation in CAG repeat expansion diseases.

View Article and Find Full Text PDF

Introduction: As aggregation underpins Tau toxicity, aggregation inhibitor peptides may have disease-modifying potential. They are therefore currently being designed and target either the VQIVYK aggregation-promoting hotspot found in all Tau isoforms or the VQIINK aggregation-promoting hotspot found in 4R isoforms. However, for any Tau aggregation inhibitor to potentially be clinically relevant for other tauopathies, it should target both hotspots to suppress aggregation of Tau isoforms, be stable, cross the blood-brain barrier, and rescue aggregation-dependent Tau phenotypes in vivo.

View Article and Find Full Text PDF

Common and divergent pathways in early stages of glutamate and tau-mediated toxicities in neurodegeneration.

Exp Neurol

December 2024

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States of America; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States of America; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States of America. Electronic address:

Article Synopsis
  • Excitotoxicity and tau-mediated toxicities are key factors in neuronal death related to Alzheimer's disease (AD), with issues like glutamate levels being critical.
  • *The main glutamate transporter, EAAT2 (GLT-1), is deficient in AD brains, leading to cell death from excitotoxicity, while tau protein buildup correlates with cognitive decline.
  • *Research using mouse models revealed that GLT-1 deficiency affects pathways linked to neuronal survival, while tau mutations disrupt endocytic pathways and mitochondria, highlighting potential therapeutic targets.*
View Article and Find Full Text PDF

Inhibition of high-fat diet-induced miRNA ameliorates tau toxicity in Drosophila.

Biochem Biophys Res Commun

November 2024

Metabolism and Neurophysiology Research Group, Disease Target Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea; Department of Bioscience, University of Science and Technology (UST), Daejeon, 34113, Republic of Korea. Electronic address:

Alzheimer's disease (AD), caused by amyloid beta (Aβ) plaques and Tau tangles, is a neurodegenerative disease characterized by progressive memory impairment and cognitive dysfunction. High-fat diet (HFD), which induces type 2 diabetes, exacerbates Aβ plaque deposition in the brain. To investigate the function of HFD in Tau-mediated AD, we fed an HFD to the Drosophila Tau model and found that HFD aggravates Tau-induced neurological phenotypes.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is one of the most progressive and prevalent types of neurodegenerative diseases in the aging population (aged >65 years) and is considered a major factor for dementia, affecting 55 million people worldwide. In the current scenario, drug-based therapies have been employed for the treatment of Alzheimer's disease but are only able to provide symptomatic relief to patients rather than a permanent solution from Alzheimer's. Recent advancements in stem cell research unlock new horizons for developing effective and highly potential therapeutic approaches due to their self-renewal, self-replicating, regenerative, and high differentiation capabilities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!